QGEN · Qiagen N.V.
$41.39
-0.06 (-0.14%)
At close · Jul 24
Market Cap
$8.53B
Shares
206.25M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.09B
+5.7%
FY2025
Net Income
$424.88M
+408.3%
FY2025
Gross Margin
62.18%
+13.3pp
FY2025
Operating Margin
22.29%
+17.4pp
FY2025
Diluted EPS
$1.94
+424.3%
FY2025
Operating Cash Flow
$654.33M
-2.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2028 (G) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2B | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B | $1.87B | $1.53B | $1.5B | $1.42B | $1.34B | $1.28B | $1.34B | $1.3B | $1.25B | $1.17B | $1.09B | $1.01B | $892.98M | |
| — | $790.5M | $1.01B | $731.62M | $756.96M | $800.84M | $637.63M | $521.16M | $500.89M | $494.98M | $493.34M | $454.33M | $479.57M | $486.49M | $430.43M | $419.94M | $371.87M | $342.75M | $293.29M | |
| — | $1.3B | $967.35M | $1.23B | $1.38B | $1.45B | $1.23B | $1.01B | $1B | $922.56M | $844.65M | $826.66M | $865.21M | $815.49M | $824.02M | $749.81M | $715.56M | $667.07M | $599.69M | |
| — | 62.18% | 48.9% | 62.77% | 64.65% | 64.43% | 65.91% | 65.86% | 66.65% | 65.08% | 63.13% | 64.53% | 64.34% | 62.63% | 65.69% | 64.1% | 65.8% | 66.06% | 67.16% | |
| — | $187.52M | $193.49M | $198.51M | $189.86M | $189.96M | $149.07M | $157.45M | $161.85M | $154.08M | $149.84M | $146.83M | $163.67M | $146.07M | $122.48M | $130.64M | $126.04M | $107.9M | $97.33M | |
| — | $457.99M | $450.93M | $459.91M | $474.22M | $456.39M | $413.68M | $391.91M | $392.28M | $375.56M | $376.32M | $359.6M | $376.14M | $371.52M | $343.55M | $307.33M | $267.48M | $244.81M | $227.41M | |
| — | $125.68M | $113.43M | $119.25M | $129.73M | $128.08M | $111.68M | $112.26M | $104.57M | $102.08M | — | — | — | — | — | — | — | — | — | |
| — | $70.34M | $84.87M | $93.8M | $93.7M | $104.4M | $103.2M | $122.6M | $118.6M | $133.8M | $137.9M | $132M | $132.9M | $126.9M | $133.1M | $110.4M | $94.9M | $78.4M | $69.4M | |
| — | $193.75M | $203.27M | $205.34M | $208.4M | $214.93M | $205.01M | $231.46M | $206.44M | $216.45M | $213.06M | $191.47M | $200.78M | $199.36M | $197.89M | $167.38M | $142.78M | $48.58M | $42.62M | |
| — | — | — | — | — | — | — | — | — | — | $79.1M | — | — | — | $41M | $74.9M | — | — | — | |
| — | $833.64M | $869.64M | $823.75M | $853.1M | $820.74M | $846.28M | $1.03B | $734.38M | $769.14M | $745.83M | $647.16M | $703.51M | $752.16M | $654.21M | $650.22M | $527.03M | $486.87M | $454.03M | |
| — | $465.85M | $97.71M | $409.94M | $531.46M | $630.08M | $386.43M | -$26.14M | $266.58M | $153.42M | $98.83M | $179.5M | $161.69M | $63.33M | $169.81M | $99.59M | $188.54M | $180.21M | $145.66M | |
| — | 22.29% | 4.94% | 20.86% | 24.82% | 27.98% | 20.66% | -1.71% | 17.75% | 10.82% | 7.39% | 14.01% | 12.02% | 4.86% | 13.54% | 8.51% | 17.34% | 17.85% | 16.31% | |
| — | $659.6M | $300.98M | $615.27M | $739.86M | $845.02M | $591.45M | $205.32M | $473.02M | $369.87M | $311.88M | $370.97M | $362.48M | $262.69M | $367.71M | $266.97M | $331.32M | $228.78M | $188.28M | |
| — | $33.26M | $43.84M | $53.41M | $58.36M | $54.48M | $71.32M | $74.19M | $67.29M | $49.69M | $39.02M | $37.4M | $39.33M | $30.88M | $23.45M | $25.36M | $27.82M | $29.64M | $37.53M | |
| — | $64.32M | $68.02M | $78.99M | $32.76M | $9.56M | $10.03M | $22.11M | $20.85M | $10.65M | $6.78M | $4.75M | $3.96M | $2.3M | $2.38M | $6.13M | $4.46M | $3.52M | $9.51M | |
| — | $24.41M | $23.44M | $19.87M | -$18.86M | -$4.25M | $53.04M | -$51.64M | -$40.84M | -$39.04M | -$41.92M | -$43.2M | -$42.3M | -$25.99M | -$24.66M | -$3.38M | -$15.42M | -$7.88M | -$26.38M | |
| — | $4.4M | $5.72M | $4.16M | $3.76M | $11.99M | $5.02M | $2.08M | $2.59M | $3.16M | $2.82M | $661K | $3.48M | $1.75M | $1.85M | — | — | — | — | |
| — | -$968K | -$426K | $0 | -$6.23M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $490.27M | $121.15M | $429.81M | $512.6M | $625.83M | $439.47M | -$77.78M | $225.74M | $114.38M | $56.91M | $136.3M | $119.39M | $37.34M | $145.15M | $96.21M | $173.12M | $172.33M | — | |
| — | $65.39M | $37.56M | $88.51M | $89.39M | $113.23M | $80.28M | -$36.32M | $35.36M | $73.98M | -$23.4M | $6.4M | $2.46M | -$31.76M | $15.62M | $1.26M | $28.81M | $34.56M | $29.76M | |
| — | $424.88M | $83.59M | $341.3M | $423.21M | $512.6M | $359.19M | -$41.46M | $190.38M | $40.39M | $80.4M | $130.15M | $116.37M | $69.07M | $129.51M | $96.04M | $144.31M | $137.77M | $89.03M | |
| — | 20.33% | 4.23% | 17.37% | 19.76% | 22.77% | 19.2% | -2.72% | 12.68% | 2.85% | 6.01% | 10.16% | 8.65% | 5.31% | 10.32% | 8.21% | 13.27% | 13.64% | 9.97% | |
| — | — | — | — | — | — | — | — | $0 | $0 | -$101K | -$246K | $568K | $25K | $31K | -$1.09M | $0 | $0 | $491K | |
| — | $522.11M | $42.88M | $311.56M | $345.79M | $429.75M | $424.99M | -$40.43M | $99.55M | $153.47M | $5.72M | $5.73M | -$14.18M | $20.89M | $157.59M | $47.19M | $158.92M | $172.76M | $29.16M | |
| USD/shares | — | $1.96 | $0.38 | $1.50 | $1.86 | $2.25 | $1.57 | -$0.18 | $0.84 | $0.18 | $0.34 | $0.56 | $0.50 | $0.30 | $0.55 | $0.41 | $0.62 | $0.67 | $0.45 |
| USD/shares | — | $1.94G | $0.37 | $1.48 | $1.84 | $2.21 | $1.53 | -$0.18 | $0.82 | $0.17 | $0.34 | $0.55 | $0.48 | $0.29 | $0.54 | $0.40 | $0.60 | $0.64 | $0.44 |
| shares | — | 217.22M | 222.62M | 228.15M | 227.58M | 227.98M | 228.43M | 226.78M | 226.64M | 228.07M | 234.8M | 233.48M | 232.64M | 234M | 235.58M | 233.85M | 232.64M | 206.93M | 196.8M |
| shares | — | 218.88M | 224.72M | 230.62M | 230.14M | 232.03M | 234.21M | 226.78M | 233.46M | 233.01M | 238.99M | 238.65M | 242.81M | 242.18M | 240.75M | 239.06M | 240.48M | 213.61M | 204.26M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2025: $1.25B in buybacks, $54.24M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 2.76×
EV/EBIT
—
Diagnostics & Research median 30.71×
P/E (TTM)
—
Diagnostics & Research median 32.60×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $2,089,999,000 | $1,978,214,000 | $1,965,311,000 | $2,141,518,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $998,448,000 | $942,009,000 | $935,281,000 | $909,616,000 | $909,690,000 | $728,577,000 | $663,869,000 | $632,660,000 |
| EMEA | $712,759,000 | $648,494,000 | $624,573,000 | $733,469,000 | $814,417,000 | $682,289,000 | $487,476,000 | $490,301,000 |
| Asia Pacific and Rest of World | $290,727,000 | $298,154,000 | $320,683,000 | $410,294,000 | $429,864,000 | $362,600,000 | $316,958,000 | $318,528,000 |
| Other Americas | $88,065,000 | $89,557,000 | $84,774,000 | $88,139,000 | $97,686,000 | $96,880,000 | $58,121,000 | $60,359,000 |
| Netherlands | $23,700,000 | $20,900,000 | $20,300,000 | $31,500,000 | $28,300,000 | $17,800,000 | $15,800,000 | $15,900,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Solutions | $803,080,000 | $748,888,000 | $697,630,000 | $660,879,000 | $638,759,000 | $460,757,000 | $465,503,000 | $461,064,000 |
| Sample Technologies | $661,265,000 | $642,031,000 | $662,991,000 | $796,932,000 | $850,636,000 | $803,867,000 | $548,365,000 | $546,636,000 |
| PCR Nucleic Acid Amplification | $308,992,000 | $300,468,000 | $300,204,000 | $390,804,000 | $433,972,000 | $363,552,000 | $224,685,000 | $236,952,000 |
| Genomics NGS | $241,775,000 | $233,608,000 | $238,910,000 | $224,797,000 | $245,066,000 | $165,570,000 | $183,768,000 | $163,383,000 |
| Product And Service Other | $74,887,000 | $53,219,000 | $65,576,000 | $68,106,000 | $83,224,000 | $76,600,000 | $104,103,000 | $93,813,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $465,851,000 | $97,711,000 | $409,938,000 | $531,460,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | 22.3% | 4.9% | 20.9% | 24.8% |
Key facts
CIK
1015820
CUSIP
N72482156
13F (30d)
52 filings
52 filers
Visit website
Investor relations